Pawasauskas et al identified hospitalized patients for risk factors associated with the need for naloxone to reverse oversedation or respiratory depression associated with opioid therapy. The authors are from the University of Rhode Island, Kent Hospital and Liberty Drug & Surgical in Rhode Island.